Cosmetic recombinant EGF · skin care
On cosmetic labels, oligopeptide-1 stands for recombinant human epidermal growth factor (EGF), a small protein signal that tells skin cells to multiply and helps wounds close. Its formal ingredient name is sh-Oligopeptide-1, and it is added to serums aimed at aging skin. Whether the cosmetic ingredient behaves like functional EGF is disputed.
Natural EGF binds the EGF receptor (EGFR) on skin cells. This receptor system is needed for normal development and upkeep of the epidermis and hair follicles; when it is deregulated, cell growth and maturation go wrong, with consequences that include poor wound repair, psoriasis-like lesions, and tumor formation, much of it mapped in mouse models1. The cosmetic rationale is that EGF applied to the skin will nudge repair pathways in photoaged skin. Two questions are unresolved: whether a protein this size passes intact outer skin in meaningful amounts, and whether the cosmetic ingredient is biologically active at all.
A 2023 review argued that sh-Oligopeptide-1 has not been shown to be active in preclinical work and should not be treated as equivalent to functional EGF2.
Human evidence for the cosmetic ingredient is thin. A 12-week randomized, double-blind pilot in 20 women aged 50 to 65 compared a recombinant EGF (oligopeptide-1) serum with a serum based on human-derived growth factors; investigators rated texture and firmness better in the recombinant group, wrinkle scores barely changed in either, and there was no placebo arm3.
In an earlier 18-person pilot in which everyone applied an EGF serum under the eyes, under-eye bag scores improved over 12 weeks, with no control group4. A 2023 review of nine clinical reports on sh-Oligopeptide-1 judged that they did not follow medical standards2. Recombinant human EGF has separately been studied as a wound medicine: in a phase 3 trial in 167 people with diabetic foot ulcers, an EGF spray added to standard care closed more ulcers completely than saline spray (73% versus 51%)5. That was a medicinal product on open wounds, not a cosmetic on intact skin.
The cosmetic ingredient is not approved as a drug by the FDA; a 2023 review describes it as authorized only for cosmetic use2. In the US, a product claimed to regenerate cells is regulated as a drug, even if it is marketed as a cosmetic6.
The cosmetic studies are small and report little; the 2026 pilot monitored participants for allergic reactions and intolerance and recorded no serious adverse events3. EGF receptor signaling drives cell growth, and its deregulation is linked to some skin diseases and tumors1; a 2023 review described the long-term risks of these cosmetics as unknown2. As with any topical product, irritation or contact allergy is possible.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.